Mithra

What we do: Mithra is a Belgian biotech company dedicated to transforming women’s health by developing innovative products focused on contraception and menopause. The company leverages the unique native estrogen estetrol (E4) to create therapies that offer improved efficacy, safety, and convenience. Mithra’s portfolio includes the contraceptive pill Estelle® and the next-generation hormone therapy Donesta®. Additionally, Mithra develops and manufactures complex therapeutics for hormone-dependent cancers and provides contract development and manufacturing services through its Mithra CDMO platform.

Where we are located: Mithra is headquartered in Liège, Belgium, at Rue Saint-Georges 5, 4000 Liège. The company operates primarily from this location.

Short history: Founded in 1999 as a spin-off from the University of Liège, Mithra has grown into a publicly listed company on Euronext (MITRA) since 2015. Key milestones include the launch of Estelle® in 2021, the first estetrol-based contraceptive, and ongoing development of Donesta®, a next-generation hormone therapy.

Organization & culture: Mithra employs approximately 300 staff members and fosters a culture of innovation and commitment to women’s health. The workforce includes a majority of women, reflecting the company’s focus and values. Teams span research and development, manufacturing, and commercial operations, emphasizing collaboration and scientific excellence.

Recent developments: In 2021, Mithra successfully launched Estelle®, the first contraceptive pill based on estetrol. The company is currently advancing Donesta®, its second product, aimed at hormone therapy for menopause. Mithra continues to expand its global reach, active in over 100 countries worldwide.